These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 25317804)

  • 21. Prognostic value of serum Tie-2 and vascular endothelial growth factor levels in cancer patients.
    Seker MM; Sancaktar E; Acibucu DO; Filiz AK; Deveci K; Bahceci A; Kacan T; Babacan N; Yuce S
    Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2929-32. PubMed ID: 24254563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
    Brufsky AM; Hurvitz S; Perez E; Swamy R; Valero V; O'Neill V; Rugo HS
    J Clin Oncol; 2011 Nov; 29(32):4286-93. PubMed ID: 21990397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients.
    Ottaiano A; Franco R; Aiello Talamanca A; Liguori G; Tatangelo F; Delrio P; Nasti G; Barletta E; Facchini G; Daniele B; Di Blasi A; Napolitano M; Ieranò C; Calemma R; Leonardi E; Albino V; De Angelis V; Falanga M; Boccia V; Capuozzo M; Parisi V; Botti G; Castello G; Vincenzo Iaffaioli R; Scala S
    Clin Cancer Res; 2006 May; 12(9):2795-803. PubMed ID: 16675573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer.
    Chin KF; Greenman J; Gardiner E; Kumar H; Topping K; Monson J
    Br J Cancer; 2000 Dec; 83(11):1425-31. PubMed ID: 11076648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is there a benefit from addiction to anti-VEGF therapy in patients with colorectal cancer?
    Saif MW
    Anticancer Res; 2013 Jun; 33(6):2377-80. PubMed ID: 23749885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
    Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab.
    Karp JE; Gojo I; Pili R; Gocke CD; Greer J; Guo C; Qian D; Morris L; Tidwell M; Chen H; Zwiebel J
    Clin Cancer Res; 2004 Jun; 10(11):3577-85. PubMed ID: 15173063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer.
    Kuramochi H; Hayashi K; Uchida K; Miyakura S; Shimizu D; Vallböhmer D; Park S; Danenberg KD; Takasaki K; Danenberg PV
    Clin Cancer Res; 2006 Jan; 12(1):29-33. PubMed ID: 16397020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels.
    Brostjan C; Gebhardt K; Gruenberger B; Steinrueck V; Zommer H; Freudenthaler H; Roka S; Gruenberger T
    Clin Cancer Res; 2008 Apr; 14(7):2065-74. PubMed ID: 18381946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of VEGF-A165b in trophoblast survival.
    Bills VL; Hamdollah-Zadeh M; Soothill PW; Harper SJ; Bates DO
    BMC Pregnancy Childbirth; 2014 Aug; 14():278. PubMed ID: 25128406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. VEGF-A165b levels are reduced in breast cancer patients at primary diagnosis but increase after completion of cancer treatment.
    Karsten MM; Beck MH; Rademacher A; Knabl J; Blohmer JU; Jückstock J; Radosa JC; Jank P; Rack B; Janni W
    Sci Rep; 2020 Feb; 10(1):3635. PubMed ID: 32108136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    Loupakis F; Cremolini C; Masi G; Lonardi S; Zagonel V; Salvatore L; Cortesi E; Tomasello G; Ronzoni M; Spadi R; Zaniboni A; Tonini G; Buonadonna A; Amoroso D; Chiara S; Carlomagno C; Boni C; Allegrini G; Boni L; Falcone A
    N Engl J Med; 2014 Oct; 371(17):1609-18. PubMed ID: 25337750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aflibercept. Metastatic colorectal cancer: at least as poorly tolerated as bevacizumab.
    Prescrire Int; 2014 Sep; 23(152):205. PubMed ID: 25325116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retraction: Association between bevacizumab-related chemotherapy regimens and serum vascular endothelial growth factor-A165b level in patients with metastatic colorectal cancer.
    Xu L; Chi C; Wang C; Zhang LM
    Eur Rev Med Pharmacol Sci; 2014 Oct; 18(20):2982. PubMed ID: 25392091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.
    Tolcher AW; Bendell JC; Papadopoulos KP; Burris HA; Patnaik A; Jones SF; Rasco D; Cox DS; Durante M; Bellew KM; Park J; Le NT; Infante JR
    Ann Oncol; 2015 Jan; 26(1):58-64. PubMed ID: 25344362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential.
    Peddi PF; Hurvitz SA
    Ther Adv Med Oncol; 2014 Sep; 6(5):202-9. PubMed ID: 25342987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.
    Gámez-Pozo A; Pérez Carrión RM; Manso L; Crespo C; Mendiola C; López-Vacas R; Berges-Soria J; López IÁ; Margeli M; Calero JL; Farre XG; Santaballa A; Ciruelos EM; Afonso R; Lao J; Catalán G; Gallego JV; López JM; Bofill FJ; Borrego MR; Espinosa E; Vara JA; Zamora P
    PLoS One; 2014; 9(10):e109611. PubMed ID: 25330188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab.
    Boisen MK; Dehlendorff C; Linnemann D; Nielsen BS; Larsen JS; Osterlind K; Nielsen SE; Tarpgaard LS; Qvortrup C; Pfeiffer P; Holländer NH; Keldsen N; Hansen TF; Jensen BB; Høgdall EV; Jensen BV; Johansen JS
    PLoS One; 2014; 9(10):e109430. PubMed ID: 25329796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression.
    Li G; Zhao L; Li W; Fan K; Qian W; Hou S; Wang H; Dai J; Wei H; Guo Y
    Oncotarget; 2014 Sep; 5(18):8317-29. PubMed ID: 25327561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.
    Chen EJ; Sowalsky AG; Gao S; Cai C; Voznesensky O; Schaefer R; Loda M; True LD; Ye H; Troncoso P; Lis RL; Kantoff PW; Montgomery RB; Nelson PS; Bubley GJ; Balk SP; Taplin ME
    Clin Cancer Res; 2015 Mar; 21(6):1273-80. PubMed ID: 25320358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.